Skip to main content

Table 1 Clinical and biological characteristics of 52 pediatric posterior fossa (PF) ependymomas

From: Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma

Variables n = 52 (%)
Age (years)  
 range 0.9–20.4
 median 3.1
Gender  
 female 24 (46.2)
 male 28 (53.8)
Extent of resection  
 GTR 34 (65.4)
 non-GTR 17 (32.7)
 n.a 1 (1.9)
Adjuvant therapy  
 no 9 (17.3)
 RTX 14 (26.9)
 CTX 5 (9.6)
 RTX and CTX 24 (46.1)
WHO grade  
 grade II 18 (34.6)
 grade III 34 (65.4)
TNC  
 positive 46 (88.5)
 negative 6 (11.5)
LAMA2  
 positive 28 (53.8)
 negative 24 (46.2)
Chromosome 1q  
 gain 10 (19.2)
 no gain 34 (65.4)
 n.a. 8 (15.4)